Salvage stereotactic body radiation therapy re-irradiation for unresectable locally recurrent nasopharyngeal rhabdomyosarcoma in a young adult: A case report

Pediatric Blood & CancerVolume 70, Issue 10 e30548 LETTER TO THE EDITOR Salvage stereotactic body radiation therapy re-irradiation for unresectable locally recurrent nasopharyngeal rhabdomyosarcoma in a young adult: A case report David S. Buchberger, Corresponding Author David S. Buchberger [email protected] Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA Correspondence David S. Buchberger, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, CA-50, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Email: [email protected]Search for more papers by this authorSamantha K. Cook, Samantha K. Cook Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorPeter M. Anderson, Peter M. Anderson Pediatric Hematology/Oncology and Bone Marrow Transplant, Cleveland Clinic Children's Hospital, Cleveland, Ohio, USA Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorDale R. Shepard, Dale R. Shepard Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorJamie A. Ku, Jamie A. Ku Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorMichael A. Fritz, Michael A. Fritz Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorRaj Sindwani, Raj Sindwani Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorPablo Recinos, Pablo Recinos Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorErin S. Murphy, Erin S. Murphy Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorShlomo A. Koyfman, Shlomo A. Koyfman Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this author David S. Buchberger, Corresponding Author David S. Buchberger [email protected] Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA Correspondence David S. Buchberger, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, CA-50, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Email: [email protected]Search for more papers by this authorSamantha K. Cook, Samantha K. Cook Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorPeter M. Anderson, Peter M. Anderson Pediatric Hematology/Oncology and Bone Marrow Transplant, Cleveland Clinic Children's Hospital, Cleveland, Ohio, USA Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorDale R. Shepard, Dale R. Shepard Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorJamie A. Ku, Jamie A. Ku Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorMichael A. Fritz, Michael A. Fritz Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorRaj Sindwani, Raj Sindwani Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorPablo Recinos, Pablo Recinos Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorErin S. Murphy, Erin S. Murphy Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this authorShlomo A. Koyfman, Shlomo A. Koyfman Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USASearch for more papers by this author First published: 17 July 2023 https://doi.org/10.1002/pbc.30548Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Casey DL, Chi YY, Donaldson SS, et al. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: a report from the Children's Oncology Group. Cancer. 2019; 125(18): 3242-3248. 2Bisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomized, phase 3 trial. Lancet Oncol. 2019; 20(11): 1566-1575. 3Meazza C, Casanova M, Luksch R, et al. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. Pediatr Blood Cancer. 2010; 55(4): 617-620. 4Anderson PM. Continuously improving ifosfamide/mesna: a winning combination. Pediatr Blood Cancer. 2010; 55(4): 599-600. 5Plutt AA, Stanton MP, Zembillas AS, et al. Excellent tolerability of ifosfamide and mesna via continuous infusion in a pediatric patient population. J Pediatr Hematol Oncol. 2022; 44(8): e1029-e1032. 6Trucco MM, Meyer CF, Thornton KA, et al. A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. Clin Sarcoma Res. 2018; 8: 21. 7Anderson PM, Thomas SM, Sartoski S, et al. Strategies to mitigate chemotherapy and radiation toxicities that affect eating. Nutrients. 2021; 13(12): 4397. 8Elledge CR, Krasin MJ, Ladra MM, et al. A multi-institutional phase 2 trial of stereotactic body radiotherapy in the treatment of bone metastases in pediatric and young adult patients with sarcoma. Cancer. 2021; 127(5): 739-747. 9Tinkle CL, Singh C, Lloyd S, et al. Stereotactic body radiation therapy for metastatic and recurrent solid tumors in children and young adults. Int J Radiat Oncol Biol Phys. 2021; 109(5): 1396-1405. 10Parsai S, Sedor G, Smile TD, et al. Multiple site SBRT in pediatric, adolescent, and young adult patients with recurrent and/or metastatic sarcoma. Am J Clin Oncol. 2021; 44(3): 126-130. 11Wakefield DV, Eaton BR, Dove APH. Is there a role for salvage re-irradiation in pediatric patients with locoregional recurrent rhabdomyosarcoma? Clinical outcomes from a multi-institutional cohort. Radiother Oncol. 2018; 129(3): 513-519. 12Vargo JA, Ward MC, Caudell JJ, et al. A multi-institutional comparison of SBRT and IMRT for definitive reirradiation of recurrent or second primary head and neck cancer. Int J Radiat Oncol Biol Phys. 2018; 100(3): 595-605. 13Ward MC, Koyfman SA, Bakst RL, et al. Retreatment of recurrent or second primary head and neck cancer after prior radiation: executive summary of the American Radium Society appropriate use criteria. Int J Radiat Oncol Biol Phys. 2022; 113(4): 759-786. 14Garau MMI. Radiobiology of stereotactic body radiation therapy (SBRT). Rep Pract Oncol Radiother. 2017; 22(2): 86-95. 15Balagamwala EH, Chao ST, Suh JH. Principles of radiobiology of stereotactic radiosurgery and clinical applications in the central nervous system. Technol Cancer Res Treat. 2012; 11(1): 3-13. Volume70, Issue10October 2023e30548 ReferencesRelatedInformation